Complete financial analysis of Lixte Biotechnology Holdings, Inc. (LIXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lixte Biotechnology Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- JTL Industries Limited (JTLIND.BO) Income Statement Analysis – Financial Results
- TCTM Kids IT Education Inc. (TEDU) Income Statement Analysis – Financial Results
- Zhejiang HangKe Technology Incorporated Company (688006.SS) Income Statement Analysis – Financial Results
- First Eagle Alternative Capital (FCRW) Income Statement Analysis – Financial Results
- Cia. Hering (HGTX3.SA) Income Statement Analysis – Financial Results
Lixte Biotechnology Holdings, Inc. (LIXT)
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 898.10K | 1.35M | 1.74M | 1.22M | 820.91K | 40.70K | 467.26K | 1.30M | 2.09M | 1.12M | 879.89K | 1.01M | 1.33M | 445.54K | 496.52K | 608.73K | 423.83K | 150.10K | 0.00 |
| General & Administrative | 4.19M | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M | 1.34M | 833.78K | 754.44K | 1.29M | 494.96K | 1.09M | 533.45K | 436.14K | 1.05M | 664.20K | 1.23M | 299.42K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.19M | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M | 1.34M | 833.78K | 754.44K | 1.29M | 494.96K | 1.09M | 533.45K | 436.14K | 1.05M | 664.20K | 1.23M | 299.42K | 32.87K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 33.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 74.00K | 0.00 | 0.00 | 0.00 | 0.00 | 128.00 | 615.00 | 592.00 | 462.00 | 0.00 |
| Operating Expenses | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 2.85M | 2.40M | 1.37M | 2.11M | 1.87M | 881.68K | 1.55M | 1.27M | 1.66M | 449.98K | 32.87K |
| Cost & Expenses | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 2.85M | 2.40M | 1.37M | 2.11M | 1.87M | 881.68K | 1.55M | 1.27M | 1.66M | 449.98K | 32.87K |
| Interest Income | 1.25K | 11.20K | 626.00 | 5.23K | 49.72K | 4.92K | 1.38K | 183.00 | 78.00 | 66.00 | 3.00 | 8.00 | 125.00 | 1.43K | 155.00 | 3.26K | 10.55K | 11.90K | 0.00 |
| Interest Expense | 0.00 | 8.88K | 7.41K | 3.67K | 0.00 | 4.92K | 1.38K | 183.00 | 78.00 | 66.00 | 3.00 | 8.00 | 125.00 | 1.43K | 1.23K | 1.23K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 205.77K | 363.11K | 3.00 | 8.00 | 199.84K | 0.00 | 128.00 | 615.00 | 592.00 | 462.00 | 0.00 |
| EBITDA | 3.21K | -1.05K | -7.95K | 1.56K | -2.49M | 4.92K | 1.38K | 183.00 | -2.44M | -2.40M | -1.37M | -3.58M | -1.87M | -881.68K | -1.55M | -1.27M | -1.65M | -561.62K | -32.87K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,220.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.09M | -6.31M | -6.72M | -3.27M | -2.49M | -2.14M | -1.81M | -2.13M | -2.65M | -2.40M | -1.37M | -2.11M | -1.87M | -881.68K | -1.55M | -1.27M | -1.66M | -499.98K | -32.87K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,323.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.21K | -1.05K | -7.95K | 1.56K | 49.72K | 4.92K | 1.38K | 183.00 | -205.70K | -363.05K | 3.00 | -1.47M | -199.71K | 1.43K | -1.08K | 2.03K | 10.55K | -38.10K | 0.00 |
| Income Before Tax | -5.09M | -6.31M | -6.73M | -3.26M | -2.44M | -2.13M | -1.81M | -2.13M | -2.85M | -2.77M | -1.37M | -3.58M | -2.07M | -880.25K | -1.55M | -1.27M | -1.65M | -488.08K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.82K | 6.79K | -1.56K | -49.72K | -9.85K | -1.81K | -2.13K | -78.00 | -66.00 | 0.00 | -8.00 | -125.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38.10K | 32.87K |
| Net Income | -5.09M | -6.30M | -6.74M | -3.26M | -2.39M | -2.13M | -1.81M | -2.13M | -2.85M | -2.77M | -1.37M | -3.58M | -2.07M | -880.25K | -1.55M | -1.27M | -1.65M | -488.08K | -32.87K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 | -1.94 | -2.68 | -3.66 | -3.74 | -1.98 | -5.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 | -1.94 | -2.68 | -3.66 | -3.74 | -1.98 | -5.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.91M | 158.20K | 1.35M | 1.13M | 1.12M | 979.94K | 930.00K | 797.00K | 779.00K | 740.00K | 693.00K | 649.00K | 586.16M | 578.94M | 488.64M | 465.41M | 445.13M | 379.17M | 45.00M |
| Weighted Avg Shares Out (Dil) | 1.92M | 158.20K | 1.35M | 1.13M | 1.12M | 979.94K | 930.29K | 797.93K | 779.89K | 740.09K | 693.05K | 649.76K | 586.16M | 578.94M | 488.64M | 465.41M | 445.13M | 379.17M | 45.00M |
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
Multiple pre-clinical studies indicate that Lixte's lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors
EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of...
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
EAST SETAUKET, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual 33rd Annual Roth Conference, being held...
WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)
LOS ANGELES--(BUSINESS WIRE)--WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)
LOS ANGELES--(BUSINESS WIRE)--WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc.
JERSEY CITY, N.J., March 2, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery...
Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional...
Why Morphic, Athenex, Lixte Biotech Are Moving Today
Morphic Holding Inc (NASDAQ: MORF), Athenex Inc (NASDAQ: ATNX) and Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) are among the healthcare movers on Monday. Morphic Jumps On Data: Morphic, a biopharma developing oral integrin therapies for treating chronic diseases, reported positive...
Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
East Setauket, March 01, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has entered into definitive agreements for the...
LIXT Stock: 8 Things to Know About Lixte Biotechnology As Shares Blast Off
Lixte Biotechnology (LIXT) stock is heading higher on Friday with heavy trading of shares despite a lack of news concerning the company. The post LIXT Stock: 8 Things to Know About Lixte Biotechnology As Shares Blast Off appeared first on...
Source: https://incomestatements.info
Category: Stock Reports